Ortin Global Ltd AI Stock Analysis
Want to see IN:ORTINGLOBE full AI Analyst Report?
Ortin Global Ltd (ORTINGLOBE) AI Stock Analysis
Ortin Global Ltd
(NSE:ORTINGLOBE)
Primarily driven by weak financial performance from severe profitability and cash flow issues despite revenue gains, followed by bearish technicals and unattractive valuation on negative earnings.
Ortin Global Ltd (ORTINGLOBE) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 105.14M
- Dividend Yield
- ―
- Average Volume (3M)
- 1,510
- Price to Earnings (P/E)
- -15.4
- Beta (1Y)
- 0.44
- Revenue Growth
- -52.63%
- EPS Growth
- 29.50%
- Country
- India
- Employees
- 8
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - Specialty & Generic
Ortin Global Ltd Business Overview & Revenue Model
Company Description
Ortin Global Ltd., established in 1986 and headquartered in Hyderabad, India, is an Indian enterprise specializing in the manufacturing and trading of pharmaceuticals, drugs, and their intermediates. The company, formerly known as Ortin Laboratories...
How the Company Makes Money
null
Ortin Global Ltd Financial Statement Overview
Summary
Strong revenue growth offset by sharply negative margins, persistent operating losses, worsening cash flows, and rising debt eroding equity.
Income Statement
25NegativeBalance Sheet
35NegativeCash Flow
20Very Negative| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 767.00K | 1.00M | 3.42M | 21.11M | 82.31M | 60.20M |
| Gross Profit | -1.07M | -1.52M | 1.28M | -16.04M | 35.79M | 26.31M |
| EBITDA | -8.92M | -7.21M | -8.23M | -63.84M | 5.50M | 4.85M |
| Net Income | -9.03M | -7.40M | -8.46M | -80.41M | -3.99M | -936.00K |
Balance Sheet | ||||||
| Total Assets | 0 | 46.47M | 37.81M | 66.64M | 207.05M | 211.97M |
| Cash, Cash Equivalents and Short-Term Investments | 6.06M | 6.06M | 3.74M | 4.59M | 4.92M | 2.56M |
| Total Debt | 0 | 10.05M | 2.50M | 18.07M | 61.44M | 64.47M |
| Total Liabilities | -12.37M | 34.10M | 18.03M | 38.40M | 97.48M | 103.32M |
| Stockholders Equity | 12.37M | 12.37M | 19.77M | 28.24M | 109.57M | 108.65M |
Cash Flow | ||||||
| Free Cash Flow | -7.75M | -5.60M | -4.14M | -47.87M | 20.23M | -2.53M |
| Operating Cash Flow | -7.75M | -5.62M | -4.10M | -47.87M | 21.48M | -2.53M |
| Investing Cash Flow | 410.00K | 390.00K | -36.00K | 120.00M | -1.25M | 82.00K |
| Financing Cash Flow | 6.79M | 7.55M | 3.28M | -34.90M | -4.71M | 9.04M |
Ortin Global Ltd Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ORTINGLOBE, the sentiment is Negative. The current price of 12.50 is below the 20-day moving average (MA) of 13.08, below the 50-day MA of 14.37, and below the 200-day MA of 15.04, indicating a bearish trend. The MACD of -0.26 indicates Negative momentum. The RSI at 45.65 is Neutral, neither overbought nor oversold. The STOCH value of 70.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:ORTINGLOBE.
Ortin Global Ltd Peers Comparison
Overall Rating
IN:PAR73Outperform
IN:BIOFILCHEM47Neutral
IN:VIVIMEDLAB46Neutral
IN:ORTINGLOBE39Underperform
IN:LASA38Underperform
IN:MANGALAM37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 73Outperform | INR 1.46B | 11.27 | ― | ― | 9.40% | 34.12% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 47Neutral | INR 506.12M | 105.85 | ― | ― | 9.31% | -82.71% | |
| 46Neutral | INR 447.74M | -0.24 | ― | ― | -39.80% | -452.04% | |
| 39Underperform | INR 105.55M | -15.45 | ― | ― | -52.63% | 29.50% | |
| 38Underperform | INR 227.96M | -1.28 | ― | ― | -95.17% | 50.07% | |
| 37Underperform | INR 459.49M | -1.21 | ― | ― | -2.37% | -92.45% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:ORTINGLOBE | Ortin Global Ltd | 12.50 | 0.58 | 4.87% | |
| IN:BIOFILCHEM | Biofil Chemicals & Pharmaceuticals Ltd. | 30.77 | -8.40 | -21.44% | |
| IN:LASA | Lasa Supergenerics Ltd. | 4.33 | -5.92 | -57.76% | |
| IN:MANGALAM | Mangalam Drugs & Organics Ltd. | 28.18 | -32.96 | -53.91% | |
| IN:PAR | Par Drugs and Chemicals Limited | 115.54 | 21.47 | 22.82% | |
| IN:VIVIMEDLAB | Vivimed Labs Limited | 5.50 | 0.60 | 12.24% |
Ortin Global Ltd Corporate Events
Ortin Global Board Approves Unaudited Results and Proposed Auditor Appointment
Ortin Global Limited said its board approved unaudited financial results for the quarter and half year ended September 30, 2026, along with the statutory auditors’ limited review report.Mathesh & Ramana resigned as statutory auditors effective Novemb...
Ortin Global Board Approves Proposed Auditor Change, Results
The release does not specify Ortin Global Limited’s industry, products or services, or market focus.The board approved unaudited financial results for the quarter and half year ended September 30, 2026, along with the statutory auditors’ limited revi...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 14, 2026
